PD-1/PD-L1 interaction(PD-1/PD-L1 相互作用)
Programmed death-1 (PD-1) is a receptor on T cells that has been shown to suppress activating signals from the T cell receptor when bound by either of its ligands, Programmed death-ligand 1 (PD-L1) or PD-L2. When PD-1 expressing T cells contact cells expressing its ligands, functional activities in response to antigenic stimuli, including proliferation, cytokine secretion, and cytotoxicity are reduced. PD-1/PD-Ligand interactions down regulate immune responses during resolution of an infection or tumor, or during the development of self tolerance.
Interference with the PD-1/PD-L1 interaction has also shown enhanced T cell activity in chronic infection systems. Chronic lymphocytic chorio meningitis virus infection of mice also exhibits improved virus clearance and restored immunity with blockade of PD-L1.
In addition to enhancing immunologic responses to chronic antigens, blockade of the PD-1/PD-L1 pathway has also been shown to enhance responses to vaccination, including therapeutic vaccination in the context of chronic infection.
- Cat.No. 产品名称 Information
-
GC25160
BMS-1001
BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.
-
GC68404
Human PD-L1 inhibitor IV
-
GC67694
PD-1/PD-L1-IN-9 hydrochloride
-
GC66394
Penpulimab
-
GC66378
Serplulimab
-
GC66344
Envafolimab
-
GC66337
Anti-Mouse PD-L1 Antibody
-
GC65920
PD1-PDL1-IN 1
-
GC65580
Sugemalimab
-
GC65290
Sintilimab
Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.
-
GC65266
Onvatilimab
-
GC65071
PD-1/PD-L1-IN 3 TFA
-
GC65033
Tislelizumab
-
GC64855
PD-1/PD-L1-IN-23
-
GC64561
Toripalimab
-
GC63984
PD-L1-IN-1
-
GC63517
PD-1-IN-24
-
GC62688
PD-1/PD-L1-IN-8
INCB086550 (PD-1/PD-L1-IN-8) is potent a PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM.
-
GC62682
BMSpep-57 hydrochloride
-
GC62658
PD-1/PD-L1-IN 7
-
GC62502
PD-1/PD-L1-IN-NP19
A PD-1/PD-L1 interaction inhibitor
-
GC62387
PD-1/PD-L1-IN-9
-
GC62253
Camrelizumab
Camrelizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities, MW: 146.3 KD.
-
GC62125
PD-1/PD-L1-IN-10
-
GC61946
TPP-1
-
GC50482
(D)-PPA 1
An inhibitor of the PD-1-PD-L1 protein-protein interaction
-
GC38740
BMS-1001 hydrochloride
An inhibitor of the PD-1/PD-L1 interaction
-
GC38131
BMS-1166 hydrochloride
A PD-1/PD-L1 interaction inhibitor
-
GC38044
Fraxinellone
A liminoid degradant with diverse biological activities
-
GC36862
PD-1-IN-22
-
GC36768
NP-12 (TFA)
-
GC36767
NP-12
A PL-1/PD-L interaction inhibitor
-
GC35913
Durvalumab
Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.
-
GC19531
Pembrolizumab
Pembrolizumab (MK-3475) 是一种人源化 IgG4 抗体,可抑制程序性细胞死亡 1 (PD-1) 受体,用于癌症免疫治疗。
-
GC34929
PD-1-IN-17 TFA
An inhibitor of PD-1 signaling
-
GC34928
PD-1-IN-17
An inhibitor of PD-1 signaling
-
GC34218
Nivolumab (BMS-936558)
Nivolumab (BMS-936558) 是一种程序性死亡受体-1 (PD-1) 阻断人 IgG4 抗体,用于治疗晚期(转移性)非小细胞肺癌。
-
GC32704
Atezolizumab (MPDL3280A)
Atezolizumab (MPDL3280A) (MPDL3280A) 是一种针对程序性死亡配体 1 (PD-L1) 的选择性人源化单克隆 IgG1 抗体,用于癌症研究。
-
GC31878
PD1-IN-2
-
GC31753
BMS-1166 (PD-1/PD-L1-IN1)
A PD-1/PD-L1 interaction inhibitor
-
GC31719
Avelumab (Anti-Human PD-L1, Human Antibody)
Avelumab (anti-PD-L1) (Bavencio, MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa.
-
GC19225
PD-1-IN-1 (CA-170)
PD-1-IN-1 (CA-170) 是一种口服给药的 VISTA 和 PD-L1 双重抑制剂。
-
GC19131
Tomivosertib
A potent inhibitor of MNK1 and MNK2
-
GC16258
PD-1/PD-L1 Inhibitor 3
A PD-1/PD-L1 interaction inhibitor
-
GC15142
PD-1/PD-L1 inhibitor 1 (BMS-1)
A PD-1/PD-L1 interaction inhibitor
-
GC16762
PD-1/PD-L1 inhibitor 2
A PD-1/PD-L1 interaction inhibitor
-
GC10469
Sulfamethoxypyridazine
A sulfonamide antibiotic